Korsana Biosciences Inc. has emerged from stealth, with its development of therapeutics to treat neurodegenerative diseases initially focused on Alzheimer’s disease.
Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported progress across its pipeline, with three distinct programs set to enter the clinic next year.
Patients with psoriatic arthritis exhibit high levels of both IL-17A and IL-17F cytokines in the synovium. Bimekizumab, a biologic that targets both IL-17A and IL-17F, was recently approved for the treatment of plaque psoriasis and psoriatic arthritis.
Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine secreted by epithelial cells that acts as an alarmin in response to environmental insults.
Paragon Therapeutics Inc. and Spyre Therapeutics Inc. jointly presented preclinical data for the novel extended half-life humanized anti-IL-23 monoclonal antibody (MAb), SPY-003, being developed for the treatment of inflammatory bowel disease (IBD).
Recent advances in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, have shown that inhibiting the interaction between the α4β7 integrin and the endothelial ligand mucosal addressin cell adhesion molecule 1 (MADCAM1) has proven useful, safe and effective.
Researchers from Paragon Therapeutics Inc. presented the preclinical characterization of ORKA-001 (PR-035), a novel half-life extended monoclonal antibody targeting the p19 subunit of IL-23, designed to treat chronic skin disorders such as plaque psoriasis.
Preventing the interaction between the cellular adhesion integrin α4β7 and endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is a validated strategy for Crohn’s disease and ulcerative colitis treatment. Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical efficacy data on SPY-001, a long-acting monoclonal antibody targeting integrin α4β7.
Researchers from Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical data for SPY-002, a novel extended half-life, fully human IgG1 monoclonal antibody (MAb) targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A), being developed for the treatment of inflammatory bowel disease (IBD).
